Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abraxane, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Reyataz and Sustiva Franchise. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

  • Revenue in USD (TTM)44.38bn
  • Net income in USD-5.08bn
  • Incorporated1933
  • Employees30.25k
  • Location
    Bristol-Myers Squibb Co430 E 29th St Fl 14NEW YORK 10016-8367United StatesUSA
  • Phone+1 (212) 546-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BMY:NYQ since
MyoKardia IncDeal completed05 Oct 202005 Oct 2020Deal completed15.84%13.77bn
Formation Biologics CorpDeal completed24 Aug 202024 Aug 2020Deal completed9.37%--
Data delayed at least 15 minutes, as of Aug 02 2021 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Gilead Sciences, Inc.26.64bn5.16bn85.72bn13.60k16.784.3517.,958,677.008.2911.059.9713.3080.1481.9219.2827.471.13----43.079.98-5.43-97.72-63.15-2.7416.09
Zoetis Inc7.01bn1.77bn95.96bn11.30k54.4923.4843.2813.683.713.7114.668.610.55381.346.71620,531.0013.9912.9916.4515.2469.6267.8725.2622.132.4710.140.637321.886.636.979.2037.0315.1319.23
Amgen, Inc.25.16bn7.09bn137.77bn24.30k19.8614.7812.965.4712.0812.0842.9116.220.40521.595.341,035,556.0011.4111.2014.2413.3675.6280.7028.1633.201.349.450.777944.508.833.25-7.370.91970.46715.16
Moderna Inc2.73bn598.17m139.17bn1.30k276.3736.21218.4950.941.251.256.829.570.3702--1.702,101,543.008.10--19.34--84.44--21.89--1.33--0.0455--1,234.34---45.34------
Bristol-Myers Squibb Co44.38bn-5.08bn151.15bn30.25k--4.1126.473.41-2.27-2.2719.6016.570.37164.326.161,467,240.00-4.242.55-5.153.1978.0272.44-11.405.971.42--0.5505192.9562.6220.75-362.14---1.693.99
Merck & Co., Inc.47.10bn4.81bn192.89bn74.00k40.32--30.674.101.892.1918.56--------636,418.90--7.26--9.4770.0569.5610.2314.95------85.462.463.97-29.059.7329.566.62
AbbVie Inc53.73bn6.60bn203.91bn48.00k31.0716.2313.203.803.723.7230.247.110.36124.955.881,143,170.004.497.735.479.7265.7173.8112.4218.070.78846.490.867197.1537.6914.91-41.90-2.408.4518.50
Data as of Aug 02 2021. Currency figures normalised to Bristol-Myers Squibb Co's reporting currency: US Dollar USD

Institutional shareholders

28.87%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2021186.79m8.36%
BlackRock Fund Advisorsas of 31 Mar 2021109.31m4.89%
SSgA Funds Management, Inc.as of 31 Mar 202190.95m4.07%
JPMorgan Investment Management, Inc.as of 31 Mar 202149.20m2.20%
Fidelity Management & Research Co. LLCas of 31 Mar 202144.76m2.00%
Wellington Management Co. LLPas of 31 Mar 202142.88m1.92%
Geode Capital Management LLCas of 31 Mar 202134.60m1.55%
Berkshire Hathaway, Inc. (Investment Management)as of 31 Mar 202131.03m1.39%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202127.88m1.25%
Dodge & Coxas of 31 Mar 202127.43m1.23%
More ▼
Data from 31 Mar 2021 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.